IP Library Granted Patent US 11,096,889
Granted Patent B2
US 11,096,889 · App. 16/717,004 · Granted Aug 24, 2021

Thermo-responsive gelling artificial lacrima

Inventors: Takeshi Yamamura (Tokyo, JP); Ayaka Yamamuro (Tokyo, JP); Emi Izukura (Tokyo, JP); Moto Kimura (Tokyo, JP); Tomohiro Otsuka (Tokyo, JP)
Assignee: WAKAMOTO PHARMACEUTICAL CO., LTD.
A61K9/0048A61K9/06A61K31/194A61K31/5383A61K47/10A61K47/12A61K47/32A61K47/38A61P27/02A61P27/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,096,889
App. No.
16/717,004
Granted
Aug 24, 2021
Kind
B2
Abstract

The present invention is an aqueous solution which contains two types of methyl celluloses, polyethylene glycol, polyvinylpyrrolidone, and citric acid or a pharmaceutically acceptable salt thereof. The composition of the present invention maintains a low viscosity around room temperature, but the composition is suddenly increased in the viscosity due to heat around the body temperature and has thixotropy even after gelation.

Claims (14)

1. An ophthalmic aqueous composition comprising:

(A) two types of methyl celluloses selected from the group consisting of methyl celluloses with label viscosities of 4, 15, 25, 100 and 400 in a total amount having a mass ratio of 1:30 to 30:1 and a combined total concentration of 0.2 to 5 w/v %;

(B) at least one polyethylene glycol having a weight average molecular weight of 300 to 20,000 at 0.5 to 4.0 w/v %;

(C) at least one polyvinylpyrrolidone selected from the group consisting of PVP K25, PVP K30, and PVP K90 at 0.5 to 4.0 w/v %; and

(D) citric acid or sodium salt thereof at 0.5 to 4.0 w/v %,

wherein the ophthalmic aqueous composition has a gelling property,

with the proviso that an ophthalmic aqueous composition comprising:

(A) methyl cellulose having a label viscosity of 4 and methyl cellulose having a label viscosity of 15 in a total amount having a mass ratio of 1:4 to 4:1 and a combined total concentration of 0.2 to 5 w/v %;

(B) polyethylene glycol having a weight average molecular weight of 4000 or 8000 at 0.5 to 4.0 w/v %;

(C) polyvinylpyrrolidone K25 at 0.5 to 4.0 w/v %; and

(D) citric acid or sodium salts thereof at 1.0 to 4.0 w/v %,

wherein all w/v % are based on the total amount of the composition, and

wherein the ophthalmic aqueous composition has a gelling property is excluded.

2. The ophthalmic aqueous of claim 1 wherein the two types of methyl celluloses are contained at a mass ratio of 1:4 to 4:1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2019
From: YAMAMURA, TAKESHI; YAMAMURO, AYAKA; IZUKURA, EMI; KIMURA, MOTO; OTSUKA, TOMOHIRO
To: WAKAMOTO PHARMACEUTICAL CO., LTD.
Reel/Frame 051321/0625 →
Priority Claims (2)
JP JP2017-086512 · Apr 25, 2017 · national
JP JP2017-249891 · Dec 26, 2017 · national
Continuity (3)
Division 16110056 · Aug 23, 2018
Continuation PCTJP2018016854 · Apr 25, 2018
Related Publication 20200121592A1 · Apr 23, 2020